Imugene Limited received HREC approval to start a Phase I clinical trial

Imugene Limited (ASX: IMU) announced that it had received approval from Human Research Ethics Committee (HREC) to start a Phase I clinical trial of its oncolytic virotherapy candidate, VAXINIA, in Australia. Ethics approval is confirmation that the company has completed all the essential pre-clinical safety and efficacy testing of VAXINIA mandatory to start human clinical trials in Australia.

The main target of the Phase 1 trial is to identify safety and an optimal biological dose of VAXINIA (CF33-hNIS) as monotherapy and later in combination with the immune checkpoint inhibitors. It will also measure efficacy, tolerability, and immune response. The company plans to run this trial for approximately 24 months and is funded from existing budgets and resources.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com